Drugs in Dev.
Genetic Disease
Discovery Platform
Japan 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : Alnylam Pharmaceuticals
Deal Size : $2,200.0 million
Deal Type : Collaboration
Alnylam and PeptiDream Enter into Collaboration Agreement
Details : PeptiDream will select, optimize, and synthesize peptides for each receptor. Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 29, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : Alnylam Pharmaceuticals
Deal Size : $2,200.0 million
Deal Type : Collaboration
